XFRA CAPITAL ADJUSTMENT INFORMATION

Realtime	Geld	Brief	Zeit
	0,260	0,322	21.12.

Realtime

Geld

Brief

Zeit

0,260

0,322

21.12.

XFRA CAPITAL ADJUSTMENT INFORMATION - 10.05.2024

Das Instrument O06 SE0002158568 EASTNINE AB EQUITY wird cum Kapitalmassnahme gehandelt am 10.05.2024 und ex Kapitalmassnahme am 13.05.2024
The instrument O06 SE0002158568 EASTNINE AB EQUITY is traded cum capital adjustment on 10.05.2024 and ex capital adjustment on 13.05.2024

Das Instrument F55 SE0017160575 LYCKEGARD GROUP AB EQUITY wird cum Kapitalmassnahme gehandelt am 10.05.2024 und ex Kapitalmassnahme am 13.05.2024
The instrument F55 SE0017160575 LYCKEGARD GROUP AB EQUITY is traded cum capital adjustment on 10.05.2024 and ex capital adjustment on 13.05.2024

Das Instrument 2BN US06777U1016 BARNES + NOBLE ED. DL-,01 EQUITY wird cum Kapitalmassnahme gehandelt am 10.05.2024 und ex Kapitalmassnahme am 13.05.2024
The instrument 2BN US06777U1016 BARNES + NOBLE ED. DL-,01 EQUITY is traded cum capital adjustment on 10.05.2024 and ex capital adjustment on 13.05.2024

Das Instrument NXOA FR0013018124 NICOX SA INH. EO 1 EQUITY wird cum Kapitalmassnahme gehandelt am 10.05.2024 und ex Kapitalmassnahme am 13.05.2024
The instrument NXOA FR0013018124 NICOX SA INH. EO 1 EQUITY is traded cum capital adjustment on 10.05.2024 and ex capital adjustment on 13.05.2024

Das Instrument HLB US43475E1055 HOLCIM NEW(U.ADR)1/5/SF2 EQUITY wird cum Kapitalmassnahme gehandelt am 10.05.2024 und ex Kapitalmassnahme am 13.05.2024
The instrument HLB US43475E1055 HOLCIM NEW(U.ADR)1/5/SF2 EQUITY is traded cum capital adjustment on 10.05.2024 and ex capital adjustment on 13.05.2024

6 Richtige für 2025

Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage: Welche Aktien werden die großen Gewinner sein? Die Auswahl an Möglichkeiten ist riesig, doch nur ein paar echte Volltreffer stechen heraus.

Ob stabiler Dividenden-Lieferant, Tech-Pionier oder spekulative Wette im Krypto-Bereich – wir haben die Märkte für Sie ausgiebig durchforstet und präsentieren Ihnen 6 Unternehmen, die große Chancen auf außergewöhnliche Kurssteigerungen besitzen. Hier sind, speziell für Sie, Ihre „6 Richtigen“ für 2025.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche Unternehmen das Potenzial besitzen, im kommenden Jahr richtig durchzustarten!

Hier klicken

Zeit	Aktuelle Nachrichten
Fr	Barnes & Noble Education, Inc. - 8-K, Current Report
09.12.	Barnes & Noble Education, Inc: Barnes & Noble Education Reports Second Quarter Fiscal Year 2025 Financial Results	2Q BNC First Day® Program Revenues Increased ~18% YOY to $235 million 2Q Net Income from Continuing Operations Improved by ~$25 million Strategic Initiatives Drive 2Q Adjusted EBITDA growth by ~$15... ► Artikel lesen
09.12.	Barnes & Noble Education, Inc. - 10-Q, Quarterly Report
06.12.	Barnes & Noble Education's CFO and chief accounting officer step down
06.12.	Barnes & Noble Education, Inc. - 8-K, Current Report

Zeit

Aktuelle Nachrichten

Barnes & Noble Education, Inc. - 8-K, Current Report

09.12.

Barnes & Noble Education, Inc: Barnes & Noble Education Reports Second Quarter Fiscal Year 2025 Financial Results

2Q BNC First Day® Program Revenues Increased ~18% YOY to $235 million 2Q Net Income from Continuing Operations Improved by ~$25 million Strategic Initiatives Drive 2Q Adjusted EBITDA growth by ~$15...
► Artikel lesen

09.12.

Barnes & Noble Education, Inc. - 10-Q, Quarterly Report

06.12.

Barnes & Noble Education's CFO and chief accounting officer step down

06.12.

Barnes & Noble Education, Inc. - 8-K, Current Report

Zeit	Aktuelle Nachrichten
05.12.	ABG SUNDAL COLLIER: Completed sale of shares in Eastnine AB
05.12.	ABG SUNDAL COLLIER: Contemplated sale of shares in Eastnine AB
29.11.	EASTNINE AB: Change of number of shares and votes in Eastnine
26.11.	EASTNINE AB: Eastnine acquires Warsaw Unit in the largest office transaction in Europe this year
26.11.	EASTNINE AB: Eastnine carries out a set-off issue to the seller of Warsaw Unit

Zeit

Aktuelle Nachrichten

05.12.

ABG SUNDAL COLLIER: Completed sale of shares in Eastnine AB

05.12.

ABG SUNDAL COLLIER: Contemplated sale of shares in Eastnine AB

29.11.

EASTNINE AB: Change of number of shares and votes in Eastnine

26.11.

EASTNINE AB: Eastnine acquires Warsaw Unit in the largest office transaction in Europe this year

26.11.

EASTNINE AB: Eastnine carries out a set-off issue to the seller of Warsaw Unit

Zeit	Aktuelle Nachrichten
10.05.	XFRA CAPITAL ADJUSTMENT INFORMATION - 10.05.2024		Das Instrument O06 SE0002158568 EASTNINE AB EQUITY wird cum Kapitalmassnahme gehandelt am 10.05.2024 und ex Kapitalmassnahme am 13.05.2024 The instrument O06 SE0002158568 EASTNINE AB EQUITY is traded... ► Artikel lesen

Zeit

Aktuelle Nachrichten

10.05.

XFRA CAPITAL ADJUSTMENT INFORMATION - 10.05.2024

Zeit	Aktuelle Nachrichten
04.12.	NICOX SA: Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream	Press Release Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream First commercialized product from the Nicox-Ocumension... ► Artikel lesen
02.12.	NICOX SA: Nicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected	Press ReleaseNicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Confirms topline results expected to be reported Q3 2025 NCX 470 demonstrated robust... ► Artikel lesen
19.11.	NICOX SA: Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial	Press Release Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial An adaptive design is a useful clinical trial design tool which allowed identification... ► Artikel lesen
17.10.	Nicox reports 1H results
17.10.	NICOX SA: Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results	Press Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3... ► Artikel lesen

Zeit

Aktuelle Nachrichten

04.12.

NICOX SA: Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

Press Release Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream First commercialized product from the Nicox-Ocumension...
► Artikel lesen

02.12.

NICOX SA: Nicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected

Press ReleaseNicox's Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected Confirms topline results expected to be reported Q3 2025 NCX 470 demonstrated robust...
► Artikel lesen

19.11.

NICOX SA: Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial

Press Release Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial An adaptive design is a useful clinical trial design tool which allowed identification...
► Artikel lesen

17.10.

Nicox reports 1H results

17.10.

NICOX SA: Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results

Press Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3...
► Artikel lesen